Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ratner, M. First PDE4 inhibitor for psoriasis hits the market but impact is uncertain. Nat Biotechnol 32, 505–506 (2014). https://doi.org/10.1038/nbt0614-505
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0614-505
- Springer Nature America, Inc.
This article is cited by
-
Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances
Drugs (2020)
-
IL-17–targeting biologics aim to become standard of care in psoriasis
Nature Biotechnology (2015)
-
Celgene shells out for antisense drug
Nature Biotechnology (2014)